Halozyme Therapeutics | HALO - Cash And Equivalent


Halozyme Therapeutics reported $309.75M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
Agios Pharmaceuticals USD 113.6M 24.47M Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
Amarin USD 131.06M 3.6M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
Baxter International USD 2.02B 51M Mar/2026
Cara Therapeutics USD 20.73M 684K Dec/2025
Cytokinetics USD 129.84M 7.32M Mar/2026
DBV Technologies USD 194.17M 124.33M Dec/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Esperion Therapeutics USD 156.16M 11.69M Mar/2026
Halozyme Therapeutics USD 309.75M 175.93M Mar/2026
Intrexon USD 9.34M 1.77M Jun/2024
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
MannKind USD 52.83M 22.05M Mar/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Pfizer USD 1.7B 561M Mar/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
United Therapeutics USD 1.28B 277.4M Mar/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025